inclusion criteria: * age ≥ 50 years * informed consent by the subject or legally authorized representative * laboratory-confirmed sars-cov-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment * peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen * onset of symptoms within 4 days of eligibility assessment. onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following sars-cov-2 infection-associated symptoms for the first time \[4\]: cough, nasal congestion, sore throat, feeling hot or feverish, myalgia, fatigue, headache, anosmia/ageusia, nausea, vomiting, and/or diarrhoea

inclusion criteria: * age ≥ 50 years * informed consent by the subject or legally authorized representative * laboratory-confirmed sars-cov-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment * peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen * onset of symptoms within 4 days of eligibility assessment. onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following sars-cov-2 infection-associated symptoms for the first time \[4\]: cough, nasal congestion, sore throat, feeling hot or feverish, myalgia, fatigue, headache, anosmia/ageusia, nausea, vomiting, and/or diarrhoea

inclusion criteria: age ≥ 50 years informed consent by the subject or legally authorized representative laboratory-confirmed sars-cov-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen onset of symptoms within 4 days of eligibility assessment. onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following sars-cov-2 infection-associated symptoms for the first time [4]: cough, nasal congestion, sore throat, feeling hot or feverish, myalgia, fatigue, headache, anosmia/ageusia, nausea, vomiting, and/or diarrhoea

inclusion criteria: age ≥ 50 years informed consent by the subject or legally authorized representative laboratory-confirmed sars-cov-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen onset of symptoms within 4 days of eligibility assessment. onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following sars-cov-2 infection-associated symptoms for the first time [4]: cough, nasal congestion, sore throat, feeling hot or feverish, myalgia, fatigue, headache, anosmia/ageusia, nausea, vomiting, and/or diarrhoea

inclusion criteria: age ≥ 50 years informed consent by the subject or legally authorized representative laboratory-confirmed sars-cov-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen onset of symptoms within 4 days of eligibility assessment. onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following sars-cov-2 infection-associated symptoms for the first time (fda, september 2020): nasal obstruction or congestion cough fever >37.3 °c sore throat body pain or muscle pain headache loss of taste or smell nausea or vomiting diarrhoea

inclusion criteria: age ≥ 50 years informed consent by the subject or legally authorized representative laboratory-confirmed sars-cov-2 infection, as determined by antigen or nucleic acid identification in any specimen, within 4 days of eligibility assessment peripheral oxygen saturation ≥ 94% on room air and not requiring supplemental oxygen onset of symptoms within 4 days of eligibility assessment. onset time of symptoms is defined as the time when the patient experienced the presence of at least one of the following sars-cov-2 infection-associated symptoms for the first time (fda, september 2020): nasal obstruction or congestion cough fever >37.3 °c sore throat body pain or muscle pain headache loss of taste or smell nausea or vomiting diarrhoea